BICO News Feed

Discover the latest news from our business areas.

Bioprinted Ear Successfully Transplanted into Patient

Share on facebook
Share on twitter
Share on linkedin

A huge day for bioprinting as doctors were able to transplant an ear bioprinted utilizing the patients own cells.

A team of doctors led by Dr. Arturo Bonilla in San Antonio have successfully transplanted the world first bioprinted construct. The patients chondrocytes were harvested and then sent to biotech company 3D Bio Therapeutics, who utilized the cells to bioprint an ear and culture it until it was ready to be transplanted by the medical team. This surgery is part of a clinical trial currently taking place to evaluate a bioprinted implant to remedy microtia, a condition where the external ear is small and not formed properly.

This represents a massive step forward in the world of bioprinting as it demonstrates the impact bioprinting can have – no longer a matter of if, but rather when will we see more advancements like this.

Microtia is a condition that occurs in one of every 2000-10000 babies. Current treatment methods for microtia involve a painstaking process to graft and shape a construct, either by taking cartilage from a patient’s rib or using other synthetic materials like PPE and then developing a construct. Conversely, with bioprinting, 3D scans are taken of the patient’s other ear to then develop a tool path for the bioprinter to follow, enabling a much more personalized and patient specific approach.

We wish the team at 3D Bio Therapeutics and all the doctors involved in this clinical trial good luck! We along with the rest of the bioprinting community are rooting for successful outcomes.

To learn more about the potential of bioprinting check out our customer spotlight on work that is being done in another realm of reconstructive surgery.

More news

June 27, 2022 | Cytena

CYTENA is officially the Innovator of the Year 2022

June 7, 2022 | Cytena

CYTENA enters long term OEM supply agreement with PAIA and launches the F.QUANT Titer high-throughput titer quantification assays for antibodies and Fc fusion proteins

June 6, 2022 | Cellink

Bioprinted Ear Successfully Transplanted into Patient

June 1, 2022 | Dispendix

ESHG & ISSCR 2022

June 1, 2022 | Scienion

SCIENION bestellt Frauke Hein als CEO

June 1, 2022 | Scienion

SCIENION Appoints Frauke Hein as CEO

May 30, 2022 | Dispendix

BICO Management Summit 2022

May 24, 2022 | Bico

Biosero, a Part of BICO Biosciences Is Awarded a New Patent for Laboratory Automation Scheduling Software

May 24, 2022 | Cellenion

Breakfast with Cellenion

May 16, 2022 | Bico

BICO joins The North American 3Rs Collaborative’s (NA3RsC) Microphysiological Systems (MPS) Initiative

May 12, 2022 | Bico

BICO Group Adds Senior IR Manager to Its Executive Management

May 11, 2022 | Dispendix

SLAS Europe 2022 – Dublin

May 6, 2022 | Cellenion

cellenONE Training & Workshop – June 2022

May 6, 2022 | Cellink

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology

May 5, 2022 | Cellink

CELLINK Announces CTR Scientific as Exclusive Distributor in Mexico

May 3, 2022 | Cytena

CYTENA and ExcellGene to Develop Automated Workflows for Biotherapeutics Cell Line Development

April 13, 2022 | Scienion

SCIENION GmbH feiert Grundsteinlegung für neue Unternehmenszentrale in Berlin Adlershof

March 3, 2022 | Cellenion

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence